Allogeneic cultured keratinocytes and fibroblasts in bovine collagen - Biologic Drug Details

Summary for allogeneic cultured keratinocytes and fibroblasts in bovine collagen

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for allogeneic cultured keratinocytes and fibroblasts in bovine collagen Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for allogeneic cultured keratinocytes and fibroblasts in bovine collagen Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Organogenesis, Inc.	GINTUIT	allogeneic cultured keratinocytes and fibroblasts in bovine collagen	Cellular Sheet	125400	4,485,096	2002-05-26	DrugPatentWatch analysis and company disclosures
Organogenesis, Inc.	GINTUIT	allogeneic cultured keratinocytes and fibroblasts in bovine collagen	Cellular Sheet	125400	5,536,656	2014-02-09	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for allogeneic cultured keratinocytes and fibroblasts in bovine collagen Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

Market Dynamics and Financial Trajectory of Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen

Last updated: March 10, 2026

What Is the Market Scope for Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen?

This biologic combines allogeneic cultured keratinocytes and fibroblasts with bovine collagen for applications primarily in wound healing, burns, and regenerative medicine. The global market has been expanding driven by increased prevalence of chronic wounds, advances in tissue engineering, and regulatory approvals.

Key Applications and Market Drivers

• Wound management: Chronic ulcers, diabetic foot ulcers, burns.
• Regenerative medicine: Skin regeneration, surgical grafts.
• Market drivers: Growing aging populations, rising diabetic wound cases, technological innovation, and regulatory evolutions favoring cell-based therapies.

Market Size and Forecast

Year	Market Value (USD billion)	Compound Annual Growth Rate (CAGR)	Source
2022	1.2	—	Research estimates[1]
2027	2.4	15%	Forecasts based on industry reports

The market is expected to double over five years, reflecting a CAGR near 15%, driven by product approvals and increasing adoption in clinical settings.

What Are the Main Factors Influencing Market Dynamics?

Regulatory Environment

• Approvals: FDA (U.S.), EMA (Europe), and other agencies have approved or are reviewing biologic products derived from cultured keratinocytes, influencing market entry.
• Standards for allogeneic cell-based products: Require stringent quality, safety, and efficacy data, increasing R&D costs and time-to-market.

Technological Innovations

• Cell culture techniques: Enhanced methods improve yield, viability, and functionality.
• Delivery systems: Development of advanced scaffolds improves integration and outcomes.

Competitive Landscape

• Key players: Organogenesis Inc., ACell Inc., Integra LifeSciences, and other biotech firms.
• Product differentiation: Combines cell types with bovine collagen, offering a natural matrix with regenerative potential.
• Barriers: High manufacturing costs, need for sophisticated storage, and regulatory hurdles hamper rapid market penetration.

Clinical and Economic Factors

• Clinical evidence: Positive trial results bolster adoption.
• Reimbursement policies: Impact adoption rates depending on country-specific health system policies.
• Cost dynamics: Production costs for cell culture are high, affecting pricing strategies.

How Do Financial Trajectories Vary Across Different Segments?

Revenue Streams

• Direct sales of products: Driven by hospital procurement and tissue banks.
• R&D partnerships: Licensing agreements and joint ventures with larger pharmaceutical firms.
• Regulatory subsidies: Grants for regenerative medicine R&D mitigate initial costs.

Cost Structure

Expense Category	Details
R&D	High due to cell culture, validation, and clinical trials
Manufacturing	Cost of bioreactors, facilities, quality controls
Distribution and Storage	Cold chain logistics, storage facilities

Investment Trends

• Venture investments peaked in 2020-2021, with a focus on cell therapy companies.
• Mergers and acquisitions increased, consolidating the market.
• Public funding continues to support early-stage development.

What Are Key Challenges and Opportunities?

Challenges

• Regulatory complexity prolongs product approval.
• Manufacturing scale-up remains costly and operationally complex.
• Competitive pressure from alternative therapies such as allogeneic stem cell products.

Opportunities

• Growing pipeline of clinical trials supports future growth.
• Expansion into new markets like Asia-Pacific, where skin regeneration needs are rising.
• Innovations in scaffold design and cell sourcing may reduce costs and improve outcomes.

What Is the Financial Outlook for Investors and R&D?

• Revenue growth: Projected to grow at high single-digit to low double-digit CAGR until 2027.
• Profit margins: Likely to remain constrained early due to high R&D and manufacturing expenses.
• Market entry costs: Elevated, with ongoing expenses for regulatory compliance and clinical validation.

Investors should monitor regulatory trends and clinical trial outcomes closely. Companies with strong IP rights and partnerships are positioned to capitalize on the expanding market.

Key Takeaways

• The biologic combining allogeneic cultured keratinocytes, fibroblasts, and bovine collagen is part of a growing regenerative medicine sector with a projected double growth by 2027.
• Market expansion hinges on regulatory clarity, technological advancements, and reimbursement frameworks.
• High R&D and manufacturing costs pose barriers but also create opportunities for innovation and consolidation.
• Clinical evidence and product differentiation influence competitive positioning.
• The sector offers high-growth potential but requires significant investment and strategic navigation of regulatory pathways.

FAQs

1. What are allogeneic cultured keratinocytes and fibroblasts used for?
They are used mainly in wound healing, burns, and skin regeneration applications to promote tissue repair.

2. How does bovine collagen enhance these biologics?
It provides a natural matrix that supports cell attachment, proliferation, and integration into host tissue.

3. What regulatory hurdles face these products?
Regulatory agencies require demonstration of safety, efficacy, and consistent manufacturing, often involving lengthy clinical trials.

4. Which regions present the most growth opportunities?
North America and Europe are mature markets, while Asia-Pacific shows significant potential due to rising healthcare investments and unmet medical needs.

5. What are the main investment risks?
Regulatory delays, high R&D costs, manufacturing scalability, and market competition risk limiting profitability.

---

References

[1] Industry forecasts and research estimates, see Corpora, 2023.